CorMedix Inc. Files 8-K Amendment
Ticker: CRMD · Form: 8-K/A · Filed: Sep 30, 2025 · CIK: 1410098
| Field | Detail |
|---|---|
| Company | Cormedix Inc. (CRMD) |
| Form Type | 8-K/A |
| Filed Date | Sep 30, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, filing, financials
TL;DR
CorMedix filed an 8-K amendment on Sept 30th for an Aug 29th event, updating financials/exhibits.
AI Summary
CorMedix Inc. filed an amendment (Amendment No. 1) to its Form 8-K on September 30, 2025, related to an event that occurred on August 29, 2025. The filing pertains to financial statements and exhibits.
Why It Matters
This amendment updates the company's filings with the SEC, providing updated information regarding financial statements and exhibits.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous report and primarily concerns administrative updates to financial statements and exhibits, not a material event.
Key Players & Entities
- CorMedix Inc. (company) — Registrant
- August 29, 2025 (date) — Earliest event date
- September 30, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- 001-34673 (string) — SEC file number
FAQ
What type of filing is this?
This is an Amendment No. 1 to a Form 8-K.
What is the name of the company filing this amendment?
The company filing this amendment is CorMedix Inc.
On what date was the earliest event reported?
The earliest event reported was on August 29, 2025.
When was this amendment filed with the SEC?
This amendment was filed on September 30, 2025.
What is the principal executive office address of CorMedix Inc.?
The address is 300 Connell Drive, Suite 4200, Berkeley Heights, NJ 07922.
Filing Stats: 795 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-09-30 16:30:29
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share CRMD Nasdaq Global Selec
Filing Documents
- ea0258874-8ka1_cormedix.htm (8-K/A) — 42KB
- ea025887401ex23-1_cormedix.htm (EX-23.1) — 2KB
- ea025887401ex99-2_cormedix.htm (EX-99.2) — 287KB
- ea025887401ex99-3_cormedix.htm (EX-99.3) — 255KB
- ea025887401ex99-4_cormedix.htm (EX-99.4) — 199KB
- ex99-2_001.jpg (GRAPHIC) — 7KB
- ex99-2_002.jpg (GRAPHIC) — 6KB
- ex99-2_003.jpg (GRAPHIC) — 1KB
- 0001213900-25-093983.txt ( ) — 1094KB
- crmd-20250829.xsd (EX-101.SCH) — 3KB
- crmd-20250829_lab.xml (EX-101.LAB) — 33KB
- crmd-20250829_pre.xml (EX-101.PRE) — 22KB
- ea0258874-8ka1_cormedix_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (a)
Financial Statements of Business Acquired
Financial Statements of Business Acquired The audited consolidated financial statements as of and for the years ended December 31, 2024 and 2023 of Melinta and unaudited condensed consolidated financial statements for the six-month period ended June 30, 2025 are attached as Exhibits 99.2 and 99.3, respectively, to this Form 8-K/A and incorporated herein by reference. Such financial statements of the Company were prepared in accordance with accounting principles generally accepted in the United States of America. (b) Pro Forma Financial Information The unaudited pro forma condensed combined financial information as of and for the year ended December 31, 2024 and the unaudited pro forma condensed combined financial information as of and for the six months ended June 30, 2025, related to the Company's acquisition of Melinta are attached as Exhibits 99.4 to this Form 8-K/A and incorporated herein by reference. (d) Exhibits Exhibit No. Description 23.1 Consent of EisnerAmper LLP. 99.2 Audited Consolidated Financial Statements of Melinta as of and for the fiscal years ended December 31, 2024 and 2023. 99.3 Unaudited Consolidated Financial Statements of Melinta as of and for the six months ended June 30, 2025. 99.4 Unaudited Pro Forma Condensed Combined Financial Information as of and for the year ended December 31, 2024 and the six months ended June 30, 2025. 104 Cover Page Interactive Data File (formatted as Inline XBRL) - 2 -
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, each registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. The signatures for each undersigned shall be deemed to relate only to matters having reference to such company and its subsidiaries. CorMedix Inc. Date: September 30, 2025 By: /s/ Joseph Todisco Name: Joseph Todisco Title: Chief Executive Officer - 3 -